Elias Siraj, MD
Endocrinology, Diabetes & Metabolism · Norfolk, VANPI 1699871533
Payments from drug & device makers
Across 680 payments — averaging $1300.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk AS$246K
- Novo Nordisk$176K
- Boehringer Ingelheim$127K
- Nevro Corp.$92K
- Globus Medical$62K
- Lexicon Pharmaceuticals, Inc.$52K
- plus $130K from 14 others
Across 10 payments — averaging $200.54 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$1K
- Eli Lilly$560
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk AS | 197 | $245,515 |
| Novo Nordisk | 152 | $175,584 |
| Boehringer Ingelheim | 104 | $126,741 |
| Nevro Corp. | 13 | $92,172 |
| Globus Medical | 13 | $61,680 |
| Lexicon Pharmaceuticals, Inc. | 15 | $52,403 |
| Lilly USA, LLC | 61 | $45,504 |
| Bayer | 23 | $38,748 |
| Dompe Farmaceutici S.p.a. | 2 | $17,400 |
| Eli Lilly | 4 | $16,720 |
| Boehringer Ingelheim International GmbH | 84 | $10,323 |
| Sanofi US Services Inc. | 1 | $615 |
| Johnson & Johnson | 1 | $375 |
| Corcept Therapeutics | 3 | $111 |
| AstraZeneca | 1 | $79 |
| Amryt Pharma Holdings Ltd | 1 | $55 |
| Xeris Pharmaceuticals, Inc. | 2 | $37 |
| Merck | 1 | $26 |
| Kyowa Kirin, Inc. | 1 | $22 |
| Intuity Medical Inc | 1 | $14 |
How this compares
$884,122 in reported general payments places this provider in the 95th percentile of 223 endocrinology, diabetes & metabolism providers in Virginia.
See all endocrinology, diabetes & metabolism providers in Virginia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other endocrinology, diabetes & metabolism in Norfolk
- Domenica RubinoArlington$3M
- Suzanne Jan de BeurCharlottesville$1.5M
- Farhad ZangenehSterling$1.2M
- Ali IranmaneshSalem$1.1M
- James MulindaRoanoke$788K
- Jeffrey SicatGlen Allen$657K
- Dewey BaileyRoanoke$645K
- James la RocqueChesapeake$576K
- Samamtha HudsonMidlothian$372K
- Stacey AndersonCharlottesville$314K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.